PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

BMJ Case Reports

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

BMJ Case Reports has 1 tracked paper indexed in Blossom (2019) from 4 authors, most often covering MDMA, across Depressive Disorders, PTSD and Anxiety Disorders.

Published Papers

Open Accessindividual

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants

In this open‑label proof‑of‑concept study, the first four participants with alcohol use disorder tolerated an 8‑week MDMA‑assisted psychotherapy programme (two MDMA sessions each) with no MDMA‑related serious adverse events or clinically significant physiological, ECG or laboratory changes, supporting safety and informing plans for a randomised placebo‑controlled trial.

Published
July 15, 2019
Journal
BMJ Case Reports
Authors
Sessa, B., Sakal, C., O'Brien S., Nutt, D. J.

Quick Facts

Papers Indexed
1
h-Index
45
Open Access
Yes
Publisher
BMJ
Country
United Kingdom
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.